DRTS

Alpha Tau MedicalB

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$10.50

+17.6% vs current

Most likely

Base case

45%

Probability

Target price

$8.00

-10.4% vs current

B-

Bear case

30%

Probability

Target price

$5.00

-44.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

This remains a cautious monitoring memo, not a high-conviction bullish setup. Primary sources confirm real progress—Japan approval, modular PMA work, five U.S. trials, DDW presentation, and roughly two years of stated cash runway—but forward visibility is still dominated by execution checkpoints and early clinical signal interpretation. The quality gate is only tentative because coverage is limited and evidence depth is thin for this name. The deterministic prior is neutral-to-negative and evidence quality started at zero in the packet, so the prudent stance is to watch for confirmation of recruitment completion, readout quality, and any evidence that Japan approval can become reimbursed commercial activity.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-02catalystDDW 2026 pancreatic data presentationHigh impact

Alpha Tau said combined pancreatic data from two Jerusalem trials will be presented orally at DDW on May 2, 2026, marking its first major gastroenterology-forum pancreatic presentation; reception matters because U.S. IMPACT enrollment is ongoing and the company said the full data will be shown there [#PR-2026-03-31].

2026-06-30eventU.S. trial enrollment and early readout checkpointsHigh impact

Management guided to ReSTART cSCC recruitment completion at end-Q1 2026, pancreatic U.S. pilot recruitment completion in Q2 2026, and an initial GBM safety readout from the first three patients in Q2 2026; as of April 15, 2026, these remain execution checkpoints rather than confirmed completions, which keeps the setup monitoring-oriented [#PR-2026-03-09].

2026-09-30catalystJapan post-market surveillance and commercial readinessHigh impact

Japan granted Shonin approval on February 24, 2026 for unresectable locally advanced or locally recurrent head and neck cancer, but Alpha Tau still must execute a 66-patient post-market surveillance study, pursue reimbursement discussions, and ramp its New Hampshire manufacturing site toward onsite production in 2026 before the approval translates into clearer revenue visibility [#PR-2026-02-24] [#PR-2026-03-09].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology